Balancing therapeutics and patient access to new cancer drugs

At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, ESMO and Congress President, Rolf A. Stahel, MD, from the University Hospital Zurich, Zurich, Switzerland, provides an overview of approaches that aim to improve patient access to new cancer medicines, including the ESMO Magnitude of Clinical Benefit Scale, which is a validated approach to stratify the magnitude of clinical benefit for cancer medicines.